Myb-transformed blood cells and their use for active ingredient screening

Abstract

The invention relates to transformed blood cells and their use for active ingredient screening. The field of application of the invention are the pharmaceutical industry and medicine. It is the object of the invention to develop hematopoietic cells that are suitable for an active ingredient screening. It was found that v-Myb, a retrovirally transduced version of c-Myb, transforms primitive erythroid precursor cells (in the following designated as Myb/bFGF-cells) in the presence of the growth factor bFGF (basis fibroblast growth factor). The reason for this are both the features of v-Myb that are taken over from c-Myb, and new properties developed in interaction with bFGF. The invention is based on transformed blood cells for elucidation of factors, components that influence the formation and differentiation of blood cells, which are characterised in that they contain Myb, in particular v-Myb, and growth factors that interact with Myb.

Dependencies are inferred from the claim text.